Media

EUROAPI and Priothera enter into CDMO collaborationto advance oncology project

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

BONESUPPORT – CERAMENT® contributes to fewer amputations – new data from Australia

Precirix to present clinical study results of its HER2-targeting CAM-H2 compound at the 2024 SNMMI annual meeting

Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)

Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024

Fusion Pharmaceuticals Shareholders Approve Acquisition By AstraZeneca

Oncopeptides publishes Q1 report 2024

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial